In vitro antiviral efficacy of amenamevir against feline herpesvirus 1

  • J Vet Med Sci. 2025 Jun 24. doi: 10.1292/jvms.25-0086.
Aoi Kikuiri  1 ,  Haruka Nishigaki  1 ,  Hikaru Fujii  1 ,  Shumpei Watanabe  1 ,  Isshu Kojima  1 ,  Shigeru Morikawa  1
Affiliations
  • 1. The Faculty of Veterinary Medicine, Okayama University of Science.
PMID: 40571578 DOI: 10.1292/jvms.25-0086
Abstract

Amenamevir (AMNV), a helicase-primase inhibitor, has recently received approval for treating human herpesvirus infections. Herein, we evaluated the efficacy of AMNV against feline herpesvirus 1 (FHV-1) in three different cell lines and compared it with that of acyclovir (ACV) and penciclovir (PCV)-nucleoside analogs currently used against FHV-1 Infection. The 50% inhibitory concentrations of AMNV against FHV-1 were comparable to those of ACV in all cell lines tested, although they were 2.0 to 21.0-fold higher than those of PCV. This is the first study to have evaluated the efficacy of AMNV against animal herpesvirus, and the results suggest that AMNV could be a new option for treating FHV-1 Infection with a novel mechanism of action.

Keywords
amenamevir; antiviral agent; feline herpesvirus type 1; helicase-primase inhibitor.
Products